Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurological Services Orlando
mi
from
Orlando, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurological Services Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Meridien Research
mi
from
Tampa, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Meridien Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Vero Beach Neurology
mi
from
Vero Beach, FL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Vero Beach Neurology
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Shepherd Center
mi
from
Atlanta, GA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Shepherd Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Josephson Wallack Munshower Neurology P.C
mi
from
Indianapolis, IN
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Josephson Wallack Munshower Neurology P.C
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Associates in Neurology
mi
from
Lexington, KY
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Associates in Neurology
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Saint Elizabeth's Medical Center
mi
from
Boston, MA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Saint Elizabeth's Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Island Neurological Assoicates, PC
mi
from
Plainview, NY
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Island Neurological Assoicates, PC
mi
from
Plainview, NY
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University Hospital and Medical Center Stony Brook New York
mi
from
Stony Brook, NY
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University Hospital and Medical Center Stony Brook New York
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Carolinas Medical Center - Neurology
mi
from
Charlotte, NC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Carolinas Medical Center - Neurology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
The Neurological Institute
mi
from
Charlotte, NC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
The Neurological Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Pmg Research Of Charlotte
mi
from
Charlotte, NC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Pmg Research Of Charlotte
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurology Specialists
mi
from
Dayton, OH
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurology Specialists
mi
from
Dayton, OH
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Providence Medical Group - Medford
mi
from
Medford, OR
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Providence Medical Group - Medford
mi
from
Medford, OR
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Providence St. Vincent Medical Center - Northwest MS Center
mi
from
Portland, OR
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Providence St. Vincent Medical Center - Northwest MS Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
The Maxine Mesinger MS Clinic/Baylor College of Medicine
mi
from
Houston, TX
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
The Maxine Mesinger MS Clinic/Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Central Texas Neurology
mi
from
Round Rock, TX
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Central Texas Neurology
mi
from
Round Rock, TX
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Integra Clinical Research
mi
from
San Antonio, TX
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Integra Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Fletcher Allen Health Care - Neurology Service
mi
from
Burlington, VT
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Fletcher Allen Health Care - Neurology Service
mi
from
Burlington, VT
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Hampton Roads Neurology
mi
from
Newport News, VA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Hampton Roads Neurology
mi
from
Newport News, VA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Neurological Associates, Inc.
mi
from
Richmond, VA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Neurological Associates, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Swedish Neuroscience Institute
mi
from
Issaquah, WA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Swedish Neuroscience Institute
mi
from
Issaquah, WA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Swedish Neuroscience Institute
mi
from
Seattle, WA
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
University of Ottawa
mi
from
Ottawa,
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
University of Ottawa
mi
from
Ottawa,
Click here to add this to my saved trials
Evaluating the Validity of an Eye Gaze Paradigm in Predicting Autism Spectrum Disorder
Evaluating the Validity of an Eye Gaze Tracking Assessment Tool in Identifying Autism Spectrum Disorder
Status: Enrolling
Updated:  1/9/2017
Cleveland Clinic Center for Autism
mi
from
Cleveland, OH
Evaluating the Validity of an Eye Gaze Paradigm in Predicting Autism Spectrum Disorder
Evaluating the Validity of an Eye Gaze Tracking Assessment Tool in Identifying Autism Spectrum Disorder
Status: Enrolling
Updated: 1/9/2017
Cleveland Clinic Center for Autism
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated:  1/9/2017
Stanford University
mi
from
Stanford, CA
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated: 1/9/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated:  1/9/2017
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated: 1/9/2017
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated:  1/9/2017
University of Utah
mi
from
Salt Lake City, UT
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated: 1/9/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated:  1/9/2017
OSU Wexner Medical Center
mi
from
Columbus, OH
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated: 1/9/2017
OSU Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated:  1/9/2017
Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET)
mi
from
Marseille,
Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status: Enrolling
Updated: 1/9/2017
Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET)
mi
from
Marseille,
Click here to add this to my saved trials
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/9/2017
A.I. Dupont Hospital for Children
mi
from
Wilmington, DE
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/9/2017
A.I. Dupont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke
Feasibility and Safety of NeuroFlo™ in Patients With Persistent Arterial Occlusion (PAO) After Failed Mechanical Revascularization
Status: Enrolling
Updated:  1/11/2017
UCLA Medical Center
mi
from
Los Angeles, CA
A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke
Feasibility and Safety of NeuroFlo™ in Patients With Persistent Arterial Occlusion (PAO) After Failed Mechanical Revascularization
Status: Enrolling
Updated: 1/11/2017
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation
Status: Enrolling
Updated:  1/11/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation
Status: Enrolling
Updated: 1/11/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Birmingham, AL
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Mobile, AL
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Phoenix, AZ
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Fort Smith, AR
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Oceanside, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Orange, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Sacramento, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
San Diego, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
San Francisco, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Stanford, CA
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Denver, CO
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Englewood, CO
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Englewood, CO
Click here to add this to my saved trials